SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories advances on USFDA completing inspection of its manufacturing facility

29 Nov 2018 Evaluate

Neuland Laboratories is currently trading at Rs. 518.00, up by 28.45 points or 5.81% from its previous closing of Rs. 489.55 on the BSE.

The scrip opened at Rs. 500.70 and has touched a high and low of Rs. 557.00 and Rs. 488.00 respectively. So far 16839 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1035.00 on 29-Nov-2017 and a 52 week low of Rs. 485.10 on 28-Nov-2018.

Last one week high and low of the scrip stood at Rs. 557.00 and Rs. 485.10 respectively. The current market cap of the company is Rs. 675.62 crore.

The promoters holding in the company stood at 36.04%, while Institutions and Non-Institutions held 38.53% and 25.43% respectively.

The United States Food and Drug Administration (USFDA) has inspected one of the Manufacturing facilities of Neuland Laboratories (Unit 2), located at Pashmylaram, Patancheru Mandal, Sangareddy District in the state of Telangana, from November 26-29, 2018. The inspection at Unit 2 by the USFDA has been successfully completed, with no observations under Form 483.

Neuland Laboratories manufactures active pharmaceutical ingredients for global pharmaceutical companies and provides end-to-end solutions for the pharmaceutical industry for chemistry-related services.

Neuland Laboratories Share Price

17693.65 393.20 (2.27%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×